Reflecting the latest clinical insights and expert consensus, this tool offers clear guidance on managing MPS VI (Maroteaux-Lamy syndrome) and direct access to the pertinent clinical publications. Here you can learn about recommended treatments for specific symptoms and issues and enzyme replacement therapy to target the underlying disease.
Overview of Mucopolysaccharidosis VI
Mucopolysaccharidosis VI (MPS VI), or Maroteaux-Lamy syndrome, is a rare lysosomal storage disorder (LSD) caused by a buildup of glycosaminoglycans (GAGs) in the bones and soft tissues of the human body.1,2 This causes a range of symptoms and conditions throughout different organ systems, including skeletal deformities, heart problems, and breathing difficulties.2
Because of the range of symptoms and conditions, MPS VI often requires the care of many different medical specialists.2
MPS VI On Command provides clinicians with easy-to-access, in-depth information regarding the different ways Mucopolysaccharidosis VI can affect the body. This tool also discusses different treatments for Maroteaux-Lamy syndrome, so that clinicians have clear guidance on what to do.